MA59093B1 - Nouveaux analogues de glp-1 - Google Patents
Nouveaux analogues de glp-1Info
- Publication number
- MA59093B1 MA59093B1 MA59093A MA59093A MA59093B1 MA 59093 B1 MA59093 B1 MA 59093B1 MA 59093 A MA59093 A MA 59093A MA 59093 A MA59093 A MA 59093A MA 59093 B1 MA59093 B1 MA 59093B1
- Authority
- MA
- Morocco
- Prior art keywords
- analogs
- present
- glp
- new
- action
- Prior art date
Links
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 title 1
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 abstract 2
- 101100337060 Caenorhabditis elegans glp-1 gene Proteins 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 230000002411 adverse Effects 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Nutrition Science (AREA)
- Immunology (AREA)
- Physiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La présente invention concerne de nouveaux analogues du glucagon like peptide-1 (glp-1) (7-37) ayant une séquence d'acides aminés avec leu ou ile au niveau c-terminal. Les nouveaux analogues sont de puissants agonistes du glp-1 avec des effets indésirables réduits et une durée d'action améliorée. La présente invention concerne en outre des dérivés acylés des nouveaux analogues qui ont une puissance et une durée d'action encore améliorées et sont adaptés à une administration orale. Les analogues de la présente invention peuvent être utiles dans le traitement du diabète et de l'obésité.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201821013109 | 2018-04-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA59093B1 true MA59093B1 (fr) | 2024-05-31 |
Family
ID=83280018
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA59093A MA59093B1 (fr) | 2018-04-05 | 2019-04-05 | Nouveaux analogues de glp-1 |
| MA52226A MA52226B1 (fr) | 2018-04-05 | 2019-04-05 | Nouveaux analogues de glp-1 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA52226A MA52226B1 (fr) | 2018-04-05 | 2019-04-05 | Nouveaux analogues de glp-1 |
Country Status (1)
| Country | Link |
|---|---|
| MA (2) | MA59093B1 (fr) |
-
2019
- 2019-04-05 MA MA59093A patent/MA59093B1/fr unknown
- 2019-04-05 MA MA52226A patent/MA52226B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MA52226B1 (fr) | 2022-08-31 |
| MA52226A (fr) | 2021-02-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20200251A1 (ar) | نظائر glp-1 جديدة | |
| Garbers et al. | Inhibition of classic signaling is a novel function of soluble glycoprotein 130 (sgp130), which is controlled by the ratio of interleukin 6 and soluble interleukin 6 receptor | |
| Rivier et al. | Potent and long-acting corticotropin releasing factor (CRF) receptor 2 selective peptide competitive antagonists | |
| RU2551977C2 (ru) | Пептидные агонисты glp-2 | |
| RU2015101826A (ru) | Применение долгодействующих пептидов glp-1 | |
| MA31242B1 (fr) | Co-agonistes des recepteurs du glucagon/glp-1 | |
| PE20221518A1 (es) | Analogos de incretina y sus usos | |
| RU2020112302A (ru) | Соединения для уменьшения вязкости биологических композиций | |
| EP2549992A2 (fr) | Méthodes de traitement utilisant des agents mobilisateurs des cellules souches | |
| Jelsing et al. | The DPP4 inhibitor linagliptin delays the onset of diabetes and preserves-cell mass in non-obese diabetic mice | |
| MA59093B1 (fr) | Nouveaux analogues de glp-1 | |
| Zahid et al. | Caerulein-and xenopsin-related peptides with insulin-releasing activities from skin secretions of the clawed frogs, Xenopus borealis and Xenopus amieti (Pipidae) | |
| CA2593201C (fr) | Methode de traitement ou de prevention de la deterioration, de blessure ou de dommage tissulaire engendre par une maladie neuro-degenerative, degenerative musculaire ou degenerative neuro-musculaire ou permettant de restaurer un tissu altere par une telle maladie | |
| US9603900B2 (en) | Use of PACAP for the treatment of viral infections in aquatic organisms | |
| Van den Burg et al. | Plasma α-MSH and acetylated β-endorphin levels following stress vary according to CRH sensitivity of the pituitary melanotropes in common carp, Cyprinus carpio | |
| US20170043014A1 (en) | Treatment of diabetes type 1 using glp-1 and anti-il-21 | |
| Gault et al. | GIP-based therapeutics for diabetes and obesity | |
| EA202290107A1 (ru) | Фармацевтические композиции на основе пептидов, являющихся коагонистами глюкагона и glp-1 | |
| EA202092017A1 (ru) | Новые аналоги glp-1 | |
| TH2001005828A (th) | Glp-1 อนาล็อกชนิดใหม่ | |
| Sokołowska-Mikołajczyk et al. | Short-term effects of human kisspeptin on LH secretion in Prussian carp (Carassius gibelio Bloch, 1782) females at two gonad maturity stages | |
| WO2024056492A1 (fr) | Compositions destinées à être utilisées dans le traitement du diabète ou de l'obésité | |
| FR3128958A1 (fr) | Composés peptidiques cycliques agonistes du récepteur kiss1r et leurs utilisations thérapeutiques | |
| Richardson et al. | Comparative thyroid endocrinology | |
| KR20250112294A (ko) | 위장관 및/또는 내분비 장애 치료를 위한 galr2 작용제의 용도 |